Video

What the impact of 44-week aflibercept data may mean in a real-world setting

Author(s):

Sheryl Stevenson,Emily Kaiser Maharjan
Conferences|ASRS Preview

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Related Videos
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
AI Optics’ portable Sentinel Camera gains FDA 510(k) clearance
January 30th 2025

AI Optics’ portable Sentinel Camera gains FDA 510(k) clearance

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome
January 28th 2025

Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope
January 27th 2025

Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope

(Image credit: AdobeStock/Саша Федюк)
January 27th 2025

Optimizing the diagnosis and treatment of evaporative dry eye through meibomian gland management

© 2025 MJH Life Sciences

All rights reserved.